Side effects and sub-types: 20 years of understanding childhood cancer
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
このコンテンツについて
Cancer Research Matters, a new Podcast from Cancer Research UK featuring some of the incredible researchers behind cancer research. The idea is to drive and provoke conversation around cancer science, how it shapes our understanding of the disease and the challenges we face as we develop therapies.
The first series focusses on the 20th anniversary of CRUK – we’ll be winding back the clock on some of the great discoveries and breakthroughs made in the past two decades and asking some leading names where they think we’ll be in another 20 years.
This episode features Professor Richard Gilbertson. Richard is a paediatric oncology clinician scientist and is the Director of the Cancer Research UK Cambridge Centre. He has dedicated his career to understanding childhood brain tumours and is perhaps known best for his work identifying different types of medulloblastoma and ependymoma – two of the most common kinds of childhood brain tumour.
He talks about the challenges and successes of the childhood cancer research community, how he sees the future of the field and some of the incredible breakthroughs his lab has made on childhood brain cancers.
Further reading
WNT signalling and brain cancer
https://link.springer.com/article/10.1007/s00401-012-0958-8
https://www.sciencedirect.com/science/article/pii/S1535610816300551
Read about CRUK’s data strategy
https://news.cancerresearchuk.org/2022/07/07/joining-the-dots-how-our-new-research-data-strategy-will-unlock-the-power-of-big-data/
See the data strategy
https://www.cancerresearchuk.org/sites/default/files/cancer_research_uk_-_research_data_strategy.pdf
Hosted on Acast. See acast.com/privacy for more information.